SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting. Three studies led by Myriad focus on breast cancer risk assessment, and four additional studies will be shared by collaborators that will cover the company’s Precise™ MRD Test, MyChoice® CDx HRD Companion Diagnostic Test, and the Myriad Collaborative Research Registry™ (MCRR).

盐湖城，2024年5月23日（环球通讯社）--基因检测和精准医学的领导者Myriad Genetics，Inc.（纳斯达克：MYGN）及其合作者将在2024年ASCO年会上分享七项研究的数据。Myriad领导的三项研究侧重于乳腺癌风险评估，另外四项研究将由合作者分享，这些研究将涵盖该公司的Precise™MRD测试，MyChoice®CDx HRD伴随诊断测试和Myriad Collaborative Research Registry™（MCRR）。

At booth 25014, Myriad will highlight the value of genetic testing and genomic insights in guiding personalized cancer treatment decisions, as well as share information about upcoming product innovations including MRD and liquid biopsy testing. New Data at ASCO Oral Presentation: Evaluation of a polygenic risk score as a predictor of early onset triple-negative breast cancer in Black women (Abstract #: 10501) Presenter: Holly J.

在25014号展位上，Myriad将强调基因检测和基因组见解在指导个性化癌症治疗决策中的价值，并分享有关即将到来的产品创新（包括MRD和液体活检检测）的信息。ASCO口头报告的新数据：评估多基因风险评分作为黑人女性早发三阴性乳腺癌的预测因子（摘要：10501）主持人：Holly J。

Pederson, MD, Director, Medical Breast Services, Cleveland ClinicDate: Saturday, June 1, 2024Time: 3:12 pm CTDescription: This study demonstrates that Myriad’s RiskScore improves upon clinical factors for the prediction of triple-negative breast cancer and early onset (<50 years) triple-negative breast cancer in Black women.

克利夫兰诊所医学乳腺服务主任Pederson医学博士日期：2024年6月1日星期六时间：下午3:12 CT描述：这项研究表明，Myriad的风险评分改善了预测黑人女性三阴性乳腺癌和早发（<50岁）三阴性乳腺癌的临床因素。

Poster: Comparison of primary versus metastatic tumor tissue sources when designing panels for whole-genome-based tumor-informed ctDNA assays in clear cell renal cell carcinoma (Abstract #3039)Date: Saturday, June 1, 2024Time: 9:00am – 12:00pm CTDescription: In a pilot study of patients with oligometastatic renal cell carcinoma, molecular residual disease (MRD) results were largely concordant with mortality status and between monitoring panels composed of thousands of probes identified from either primary or metastatic tumor.

海报：在透明细胞肾细胞癌中设计基于全基因组的肿瘤知情ctDNA检测小组时，原发性和转移性肿瘤组织来源的比较（摘要#3039）日期：2024年6月1日星期六时间：上午9:00–下午12:00 CT描述：在一项针对寡转移性肾细胞癌患者的初步研究中，分子残留病（MRD）结果与死亡率状态以及由数千个从原发性或转移性肿瘤中鉴定的探针组成的监测小组之间基本一致。